BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pirtobrutinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Pirtobrutinib\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06466122-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT06466122)
DESCRIPTION:Pirtobrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients Wit
 h CLL or SLL Resistant to Covalent BTKi\nEstimated primary completion: 31 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pirtob
 rutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06466122
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06522386-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT06522386)
DESCRIPTION:Pirtobrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: GATE1: 
 A Multicenter Phase II Study of Pirtobrutinib\, Rituximab and Venetoclax C
 ombination Therapy for Patients With Previously Untreated Mantle Cell Lymp
 homa\nEstimated primary completion: 28 February 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pirtobrutinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06522386
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05529069-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT05529069)
DESCRIPTION:Pirtobrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Phase I
 I Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantl
 e Cell Lymphoma) Patients\nEstimated primary completion: 28 April 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/pirtobrutinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05529069
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06333262-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT06333262)
DESCRIPTION:Pirtobrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leuk
 emia\nEstimated primary completion: 1 July 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pirtobrutinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06333262
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07744737-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07744737)
DESCRIPTION:Pirtobrutinib\, phase 2.\nStudy: Pirtobrutinib + R-CHOP for Unt
 reated Non-GCB DLBCL\nEstimated primary completion: 30 July 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07744737
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07744750-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07744750)
DESCRIPTION:Pirtobrutinib\, phase 2.\nStudy: Pirtobrutinib+Sonrotoclax（PS
 ) Regimen in the Treatment of B-Cell Lymphoma\nEstimated primary completio
 n: 31 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pi
 rtobrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07744750
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05254743-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Pirtobrutinib: Phase 3 readout est. (NCT05254743)
DESCRIPTION:Pirtobrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With
  Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)\nEsti
 mated primary completion: October 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pirtobrutinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05254743
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04662255-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pirtobrutinib: Phase 3 readout est. (NCT04662255)
DESCRIPTION:Pirtobrutinib\, phase 3\, Mantle Cell Lymphoma.\nStudy: Study o
 f BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients W
 ith Mantle Cell Lymphoma (MCL)\nEstimated primary completion: November 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pirtobrutinib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04662255
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04623541-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pirtobrutinib: Phase 1/2 readout est. (NCT04623541)
DESCRIPTION:Pirtobrutinib\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStud
 y: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refr
 actory Chronic Lymphocytic Leukemia and Richter's Syndrome\nEstimated prim
 ary completion: December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/pirtobrutinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT04623541
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07685717-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07685717)
DESCRIPTION:Pirtobrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocy
 tic Leukemia\nEstimated primary completion: 31 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pirtobrutinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07685717
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06043674-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280115
DTEND;VALUE=DATE:20280116
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT06043674)
DESCRIPTION:Pirtobrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin\, Pirt
 obrutinib\, or Atezolizumab in Richter's Transformation\nEstimated primary
  completion: 15 January 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pirtobrutinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06043674
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06721013-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Pirtobrutinib: Phase 1/2 readout est. (NCT06721013)
DESCRIPTION:Pirtobrutinib\, phase 1/2.\nStudy: A Study of Pirtobrutinib in 
 Participants With Immune Thrombocytopenia\nEstimated primary completion: F
 ebruary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pirtobr
 utinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06721013
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07207785-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07207785)
DESCRIPTION:Pirtobrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Pirtobr
 Utinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Ce
 ll Lymphoma\nEstimated primary completion: 1 February 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pirtobrutinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07207785
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07231952-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280411
DTEND;VALUE=DATE:20280412
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07231952)
DESCRIPTION:Pirtobrutinib\, phase 2.\nStudy: A Study of Pirtobrutinib\, Ven
 etoclax\, and Rituximab in People With Waldenström's Macroglobulinemia (W
 M)/Lymphoplasmacytic Lymphoma (LPL)\nEstimated primary completion: 11 Apri
 l 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pirtobrutinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072
 31952
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05536349-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280425
DTEND;VALUE=DATE:20280426
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT05536349)
DESCRIPTION:Pirtobrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Time-limited Triplet Combination of Pirtobrutinib\, Venetoclax\, and Obin
 utuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (
 CLL) or Richter Transformation (RT)\nEstimated primary completion: 25 Apri
 l 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pirtobrutinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT055
 36349
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622784-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07622784)
DESCRIPTION:Pirtobrutinib\, phase 2.\nStudy: Pirtobrutinib Maintenance Afte
 r CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma\nEstimated prima
 ry completion: June 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pirtobrutinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07622784
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06588478-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT06588478)
DESCRIPTION:Pirtobrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participan
 ts With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocy
 tic Lymphoma\nEstimated primary completion: June 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pirtobrutinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06588478
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05990465-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Pirtobrutinib: Phase 1 readout est. (NCT05990465)
DESCRIPTION:Pirtobrutinib\, phase 1\, Mantle Cell Lymphoma.\nStudy: LV20.19
  CAR T-Cells in Combination With Pirtobrutinib for Relapsed\, Refractory B
 -cell Malignancies\nEstimated primary completion: July 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pirtobrutinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05990465
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07744724-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07744724)
DESCRIPTION:Pirtobrutinib\, phase 2.\nStudy: Pirtobrutinib+Pola-R-CHP for N
 ewly Diagnosed Non-GCB DLBCL\nEstimated primary completion: 31 July 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pirtobrutinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07744724
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06252675-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT06252675)
DESCRIPTION:Pirtobrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Glofita
 mab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma\nEs
 timated primary completion: 31 July 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/pirtobrutinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06252675
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07416890-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280805
DTEND;VALUE=DATE:20280806
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07416890)
DESCRIPTION:Pirtobrutinib\, phase 2.\nStudy: Thiotepa in Combination With P
 irtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail
  or Relapsed/Refractory Primary or Secondary Central Nervous System Lympho
 ma\nEstimated primary completion: 5 August 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pirtobrutinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07416890
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07774299-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280825
DTEND;VALUE=DATE:20280826
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07774299)
DESCRIPTION:Pirtobrutinib\, phase 2.\nStudy: Pirtobrutinib Combined With BE
 AM for ASCT in Relapsed and Refractory DLBCL\nEstimated primary completion
 : 25 August 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pir
 tobrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07774299
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624799-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07624799)
DESCRIPTION:Pirtobrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Imm
 uno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chr
 onic Lymphocytic Leukemia (CLL).\nEstimated primary completion: 1 Septembe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pirtobrutinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076
 24799
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07812493-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07812493)
DESCRIPTION:Pirtobrutinib\, phase 2.\nStudy: Pirtobrutinib Plus Methotrexat
 e-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement\nEstima
 ted primary completion: 1 September 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/pirtobrutinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07812493
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255963-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07255963)
DESCRIPTION:Pirtobrutinib\, phase 2.\nStudy: Pirtobrutinib\, Lisaftoclax\, 
 and Rituximab in the Treatment of R/R DLBCL\nEstimated primary completion:
  30 September 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 irtobrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07255963
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684950-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07684950)
DESCRIPTION:Pirtobrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Lisafto
 clax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma Aft
 er BTK-Targeted Therapy\nEstimated primary completion: 30 October 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/pirtobrutinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07684950
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06263491-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT06263491)
DESCRIPTION:Pirtobrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Phase I
 I Study of Pirtobrutinib\, Rituximab (PR) in Previously Untreated Low and 
 Intermediate Risk MCL (Mantle Cell Lymphoma) Patients\nEstimated primary c
 ompletion: 1 November 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pirtobrutinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06263491
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07944651-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20281208
DTEND;VALUE=DATE:20281209
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07944651)
DESCRIPTION:Pirtobrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Pirtobr
 utinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refractory Ma
 ntle-Cell Lymphoma Following Covalent BTK-Inhibitor Failure\nEstimated pri
 mary completion: 8 December 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pirtobrutinib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07944651
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052695-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pirtobrutinib: Phase 1/2 readout est. (NCT07052695)
DESCRIPTION:Pirtobrutinib\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStud
 y: Mosunetuzumab for CLL MRD Clearance\nEstimated primary completion: 31 D
 ecember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pirtobr
 utinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07052695
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07350850-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07350850)
DESCRIPTION:Pirtobrutinib\, phase 2.\nStudy: A Multicenter\, Prospective Cl
 inical Trial With a Concurrent Control Evaluating Methotrexate Combined Wi
 th Rituximab\,Sintilimab and Pirtobrutinib vs. Investigator-Selected Stand
 ard of Care in Treatment-Naive PCNSL\nEstimated primary completion: 31 Dec
 ember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pirtobrut
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07350850
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05734495-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20290125
DTEND;VALUE=DATE:20290126
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT05734495)
DESCRIPTION:Pirtobrutinib\, phase 2.\nStudy: Pirtobrutinib and Venetoclax i
 n Waldenström Macroglobulinemia\nEstimated primary completion: 25 January
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pirtobrutinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0573
 4495
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06812715-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT06812715)
DESCRIPTION:Pirtobrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutin
 ib After Previous Treatment With Zanubrutinib\nEstimated primary completio
 n: May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pirtobru
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06812715
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06553872-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT06553872)
DESCRIPTION:Pirtobrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Phase 2
  Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleuce
 l in R/R MCL\nEstimated primary completion: August 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pirtobrutinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06553872
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07516093-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Pirtobrutinib: Phase 3 readout est. (NCT07516093)
DESCRIPTION:Pirtobrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL\nEstimated primary c
 ompletion: October 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pirtobrutinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07516093
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07428707-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20300201
DTEND;VALUE=DATE:20300202
SUMMARY:Pirtobrutinib: Phase 1 readout est. (NCT07428707)
DESCRIPTION:Pirtobrutinib\, phase 1\, Chronic Lymphocytic Leukemia.\nStudy:
  Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib\nEstima
 ted primary completion: 1 February 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pirtobrutinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07428707
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07162181-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07162181)
DESCRIPTION:Pirtobrutinib\, phase 2.\nStudy: Long-Term Safety of Pirtobruti
 nib in Participants With Previously Treated Types of Blood Cancers\nEstima
 ted primary completion: May 2030. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pirtobrutinib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07162181
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06876662-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Pirtobrutinib: Phase 4 readout est. (NCT06876662)
DESCRIPTION:Pirtobrutinib\, phase 4\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study of (LY3527727) Pirtobrutinib in Participants With Previously Trea
 ted Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin
  Lymphoma\nEstimated primary completion: May 2030. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pirtobrutinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06876662
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06876649-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Pirtobrutinib: Phase 4 readout est. (NCT06876649)
DESCRIPTION:Pirtobrutinib\, phase 4\, Chronic Lymphocytic Leukemia.\nStudy:
  A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobr
 utinib\nEstimated primary completion: May 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pirtobrutinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06876649
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07218341-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Pirtobrutinib: Phase 4 readout est. (NCT07218341)
DESCRIPTION:Pirtobrutinib\, phase 4\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphoc
 ytic Leukemia/Small Lymphocytic Lymphoma\nEstimated primary completion: Ma
 y 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pirtobrutinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072
 18341
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07917780-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20300515
DTEND;VALUE=DATE:20300516
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07917780)
DESCRIPTION:Pirtobrutinib\, phase 2.\nStudy: A Trial to Evaluate the Effica
 cy of Pirtobrutinib and Epcoritamab Compared With R-(Mini)-CHOP for Treatm
 ent of Patients With DLBCL-type Richter Transformation\nEstimated primary 
 completion: 15 May 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pirtobrutinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07917780
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07860775-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20301015
DTEND;VALUE=DATE:20301016
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07860775)
DESCRIPTION:Pirtobrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma W
 ith Pirtobrutinib in Combination With Epcoritamab if the Disease Comes Bac
 k After Previous Treatment.\nEstimated primary completion: 15 October 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pirtobrutinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07860775
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07831395-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07831395)
DESCRIPTION:Pirtobrutinib\, phase 2.\nStudy: Rituximab\, Pirtobrutinib\, Li
 saftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed 
 From CLL\nEstimated primary completion: 31 December 2030. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pirtobrutinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07831395
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06967610-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20310601
DTEND;VALUE=DATE:20310602
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT06967610)
DESCRIPTION:Pirtobrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Phase II Study of Combined Pirtobrutinib\, Venetoclax and Obinutuzumab (P
 VO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic
  Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).\nEstimated primary complet
 ion: 1 June 2031. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pir
 tobrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06967610
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948786-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT06948786)
DESCRIPTION:Pirtobrutinib\, phase 2.\nStudy: Pirtobrutinib and Mosunetuzuma
 b for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma
 \, PROMOTE-FL Trial\nEstimated primary completion: 31 July 2031. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pirtobrutinib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06948786
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06390956-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT06390956)
DESCRIPTION:Pirtobrutinib\, phase 2.\nStudy: Pirtobrutinib in Combination W
 ith Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL
 )\nEstimated primary completion: December 2031. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pirtobrutinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06390956
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05833763-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT05833763)
DESCRIPTION:Pirtobrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: A Phase
  2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients 
 With Prior BTK Inhibitor Exposure.\nEstimated primary completion: April 20
 32. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pirtobrutinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0583376
 3
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285590-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07285590)
DESCRIPTION:Pirtobrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Clinica
 l Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituxima
 b in Patients With Mantle Cell Lymphoma\nEstimated primary completion: Dec
 ember 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pirtobrut
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07285590
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07548450-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20341130
DTEND;VALUE=DATE:20341201
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07548450)
DESCRIPTION:Pirtobrutinib\, phase 2.\nStudy: Mosunetuzumab in Combination W
 ith Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macr
 oglobulinemia (MPOWER)\nEstimated primary completion: November 2034. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pirtobrutinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07548450
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220187-3359@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20351001
DTEND;VALUE=DATE:20351002
SUMMARY:Pirtobrutinib: Phase 3 readout est. (NCT07220187)
DESCRIPTION:Pirtobrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnos
 ed Richter Transformation\, The PIRAMID Trial\nEstimated primary completio
 n: 1 October 2035. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pi
 rtobrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07220187
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
